SYNAPTOTAGMIN AND COLLAPSIN RESPONSE MEDIATOR PROTEIN AS BIOMARKERS FOR TRAUMATIC BRAIN INJURY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 2, 2012
app pub date -
Dec 27, 2011
filing date -
Feb 6, 2007
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological samples after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (biological samples). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully